The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Understanding the differences between colds, flu, and RSV can help in identifying the illness you're dealing with, the ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...

The letter, signed by 79 medical societies, expresses concern over recent federal immunization review policies and asks that ...

Still suffering from an irritating cough weeks after recovering from a cold or flu? We investigated why your cough won't go ...

A major UK-led clinical trial has found that a treatment commonly used to help premature babies breathe offers no benefit for ...

By a 5-2 vote, the Advisory Committee on Immunization Practices endorsed Merck’s Enflonsia for babies born during or entering their first RSV season.

FEV1/FVC was significantly lower in young adults who had severe bronchiolitis during infancy vs those who did not. Severe bronchiolitis during infancy may contribute to irreversible airway obstruction ...

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older: London, UK Saturday, June 14, 2025, 10:00 Hrs [IST] GSK plc announced tha ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older. CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) tod ...